Characteristics of Thyroid Eye Disease Patients at Wahidin Sudirohusodo Hospital Makassar

Usna Jayanti; Sri Irmandha Kusumawardhani; Andi Millaty Halifah Dirgahayu Lantara; Ratih Natasha Maharani; Hanna Aulia Namirah

doi:10.22487/htj.v11i3.1704

Authors

Usna Jayanti Faculty of Medicine, Universitas Muslim Indonesia
Sri Irmandha Kusumawardhani Department of Ophthalmology, Faculty of Medicine, Universitas Muslim Indonesia
Andi Millaty Halifah Dirgahayu Lantara Department of Physiology, Faculty of Medicine, Universitas Muslim Indonesia
Ratih Natasha Maharani Department of Ophthalmology, Faculty of Medicine, Universitas Muslim Indonesia
Hanna Aulia Namirah Department of Ophthalmology, Faculty of Medicine, Universitas Muslim Indonesia

DOI:

https://doi.org/10.22487/htj.v11i3.1704

Keywords:

Thyroid Eye Disease (TED), patient characteristics, management

Abstract

Background: Thyroid Eye Disease (TED) is an autoimmune orbital disorder frequently associated with Graves’ disease, marked by orbital fat expansion and extraocular muscle swelling that may impair vision and quality of life. Objective: To describe the characteristics of TED patients at RSUP Wahidin Sudirohusodo Makassar based on age, gender, clinical manifestations, management, and smoking history. Methods: A descriptive study of 55 TED patients recorded at RSUP Wahidin Sudirohusodo Makassar. Results: Most patients were aged 20–44 years (60%), followed by 45–64 years (34.55%) and 13–19 years (5.45%), with no cases above 65 years. Females predominated (61.82%). The most common symptom was proptosis (100%), followed by excessive tearing (49.09%), red eyes (27.27%), refractive errors (23.64%), diplopia (10.91%), pain during eye movement (7.27%), and photophobia (7.27%). The main treatment was intravenous methylprednisolone plus thiamazole (47.27%), followed by intravenous methylprednisolone alone (18.18%), thyrozol (18.18%), and propranolol (9.09%). One patient (1.82%) underwent orbital decompression. Active smoking was reported in 32.73% of patients. Conclusion: TED patients were predominantly females aged 20–44 years, with proptosis as the leading manifestation. The most common management was intravenous methylprednisolone combined with thiamazole. Smoking may worsen disease severity

References

ng TD, Stocker DJ, Chou EL, Burch HB. Update on Clinical Management of Graves Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am 2022;51(2):287–304.

Fitrada L, Boesoirie SF. Karakteristik Klinis Pada Penderita Thyroid-Associated Ophthalmopathy (Tao), Di Pusat Mata Nasional Rumah Sakit Mata Cicendo. Fakultas Kedokteran Universitas Padjadjaran 2019;1–8.

Munandar M. Hubungan Clinical Activity Score Dengan Nospecs Pada Pasien Thyroid-Associated Orbitopathy. Fakultas Kedokteran Universitas Padjadjaran 2022;1–49.

Pokhrel B, Bhusal K. Graves Disease. ncbi [homepage on the Internet] 2023;1–9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448195/

Andressa Nugroho YW, Limantoro C, Arimadyo A. Hubungan Faktor Risiko Terhadap Kejadian Ophthalmopathy Graves. Jurnal Kedokteran Diponegoro 2019;8(4):1248–1256.

Arief M, Made Wirka I, Setyawati T. Karakteristik Pasien Ileus Obstruktif di Rumah Sakit Universitas Tadulako Palu. 2020;

Szelog J, Swanson H, Matthew C, Sniegowski, Lyon D. Thyroid Eye Disease. Mo Med 2022;343–350.

Pramita I, Yuliawati P, Utari N, Djelantik A, Manuaba I. Karakteristik Pasien Proptosis di Poliklinik Mata Divisi Rekonstruksi, Okuloplasti, dan Onkologi Rumah Sakit Umum Pusat Sanglah, Denpasar. Medicina (B Aires) 2019;50(2):260–265.

Shah S, Patel B. Thyroid Eye Disease. ncbi [homepage on the Internet] 2023;1–9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582134/

Subekti I, Soewondo P, Soebardi S, et al. Practical Guidelines Management of Graves Ophthalmopathy. Acta Medica Indonesiana - The Indonesian Journal Internal Medicine 2019;51:364–371.

Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population. Ophthalmic Plast Reconstr Surg 2021;37(6):583–591.

Rukmana DSPA, Ramzi RN, Dhuarte J, Jaya F, Anugrahsari S. Potensi Teprotumumab dalam Pengobatan Penyakit Mata Tiroid Aktif (TED). Jurnal MedScientiae 2024;3(2):120–128.

Jordan M, Mussatto C, Chu R, Al-Sabbagh M, Timoney P, Sokol J. Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study. Kans J Med 2023;16(1):62–64.

Subagio Y. Faktor Risiko Merokok Pada Pasien Thyroid Eye Disease. Fakultas Kedokteran Universitas Padjadjaran 2020;1–53.

Syamsi N, Tanra AAM, HS MR. Hubungan Antara Merokok Dengan Gambaran Fungsi Ginjal Pada Karyawan PT.X. Healthy Tadulako Journal 2021;7(3).

Setiadi F, Kumala S, Utami R H, Subhan A. Analisis Faktor-Faktor Yang Mempengaruhi Outcome Terapi Pasien Pneumonia Di Rumah Sakit Umum Pusat Fatmawati Jakarta. Healthy Tadulako Journal 2020;5(3).

Haryanto Ali I, Nurzahra Male S. Karakteristik Epidemiologi Penyakit Infeksi Saluran Pernapasan Akut (Ispa) Di Puskesmas Telaga Biru. Healthy Tadulako Journal (Jurnal Kesehatan Tadulako 2024;10(3):370–378